Table 5.

Recommended dose of GO in patients with AML.

Newly diagnosed CD33-positive AML a (combination regimen)	1 induction cycle: 3 mg/m2 (up to 4.5 mg vial) on days 1, 4, and 7 in combination with daunorubicin and cytarabine.	2 consolidation cycles: 3 mg/m2 on day 1 (up to 4.5 mg vial) in combination with daunorubicin and cytarabine
Newly diagnosed CD33-positive AML (single-agent regimen):	1 induction cycle: 6 mg/m2 as a single agent on days 1 and 3 mg/m2 on day 8.	8 continuation cycles: 2 mg/m2 as a single agent on day 1 every 4 weeks.
CD33-positive or relapse-resistant AML (single-agent regimen)	1 single cycle: 3 mg/m2 (up to a 4.5 mg vial) on days 1, 4 and 7

^a AML: acute myeloid leukemia.